7 completed, 5 unknown, 2 withdrawn. 14 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 14 | Completed 7, Unknown 5, Withdrawn 2 |
Follow Olfaction Disorders: new trials by email Literature Review of Olfaction Disorders trials Research Report on Olfaction Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olfactory Performance in Culinary Arts Students Olfactory training - Loss of Smell, Olfactory Disorder | Phase 4 | Unknown | Leigh Sowerby | 120 | 2023-09-25 | 2023-10-06 |
| Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. Aerosolized 13 cis retinoic acid plus Vitamin D, Aerosolized All trans retinoic acid plus Vitamin D, Standard therapy - Post COVID-19 Anosmia (Loss of Smell) | Phase 4 | Unknown | Kafrelsheikh University | 10000 | 2021-11-01 | 2021-11-11 |
| Influence of Olfaction Essential Oils on the Consumption of Benzodiazepine Receptor Agonists & Z-Drugs (BZRAs) Prescribed as " if Needed " in Psychiatric Outpatients (HECBA-PSY). Essences and Essential Oils - Psychiatric Disorder, Benzodiazepine Withdrawal | Phase 4 | Unknown | Etablissement Public de Santé Barthélemy Durand | 50 | 2021-04-19 | 2022-10-18 |
| Anosmia and / or Ageusia and Early Corticosteroid Use Early-Dexamethasone, Late dexamethazone - Covid19, Anosmia | Phase 4 | Unknown | ClinAmygate | 300 | 2021-03-30 | 2023-09-06 |
| Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19) Olfactory retraining, corticosteroid nasal irrigation, smell household Items - Olfactory Disorder | Phase 4 | Withdrawn | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2021-01-10 | 2025-08-01 | |
| Olfactory Disfunction and Co-ultraPEALut co-ultraPEALut, Olfactory Rehab, PEA-LUT 1 sachet - Anosmia, Covid19 | Phase 4 | Completed | University Of Perugia | 200 | 2020-11-15 | 2022-11-16 |
| BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 BNO 1030, Standard care - Covid19, Nasopharyngitis | Phase 4 | Completed | Ivano-Frankivsk National Medical University | 133 | 2020-05-01 | 2021-03-15 |
| Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly Donepezil - Alzheimer Disease, Mild Cognitive Impairment | Phase 4 | Completed | New York State Psychiatric Institute | 121 | 2013-10-01 | 2020-07-13 |
| Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil Donepezil, Atropine - Mild Cognitive Impairment | Phase 4 | Completed | New York State Psychiatric Institute | 41 | 2012-08-01 | 2018-07-09 |
| Taste, Smell and Chemotherapy (TASTY) Dexa scan, audiogram, measurement of heart rate variability and baroreflex sensitivity - Testicular Cancer | Phase 4 | Completed | University Medical Center Groningen | 140 | 2012-06-01 | 2024-04-19 |
| A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Rasagiline, Placebo - Parkinson's Disease | Phase 4 | Unknown | The Parkinson's Institute | 36 | 2009-11-01 | 2013-12-02 |
| Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline Azilect 1mg, Placebo - Parkinson´s Disease | Phase 4 | Completed | Technische Universität Dresden | 34 | 2009-05-01 | 2012-02-07 |
| Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis Placebo, Xolair - Chronic Sinusitis | Phase 4 | Withdrawn | University of California, San Francisco | 2008-01-01 | 2020-02-05 | |
| Effect of Postoperative Additive Systemic Steroids in CRSwNP Systemic Steroid (Prednisolone), Placebo - Sinusitis, Chronic | Phase 4 | Completed | Friedrich-Alexander-Universität Erlangen-Nürnberg | 106 | 2005-01-18 | 2021-06-07 |
Anosmia (14) · COVID-19 (4) · Alzheimer Disease (2) · Cognitive Dysfunction (2) · Nasal Obstruction (2) · Parkinson Disease (2) · Anxiety Disorders (1) · Bronchiolitis Obliterans Syndrome (1) · Cognition Disorders (1) · Cough (1) · Facial Pain (1) · Fever (1) · Mental Disorders (1) · Myalgia (1)
Nervous System Diseases (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Sensation Disorders (14) · Signs and Symptoms (14) · Infections (6) · Respiratory Tract Diseases (6) · Respiratory Tract Infections (6) · Lung Diseases (5) · Brain Diseases (4) · Central Nervous System Diseases (4) · Coronaviridae Infections (4) · Coronavirus Infections (4) · Neurodegenerative Diseases (4)
Donepezil (2) · Olfactory Training (2) · Standard of Care (2) · rasagiline (2) · Absorptiometry, Photon (1) · Atropine (1) · Dexamethasone (1) · Hearing (1) · Nasal Lavage (1) · Oils, Volatile (1) · Omalizumab (1) · Prednisolone (1) · Vitamin D (1) · co-ultraPEALut (1) · imupret (1)
New York State Psychiatric Institute (2) · ClinAmygate (1) · Etablissement Public de Santé Barthélemy Durand (1) · Friedrich-Alexander-Universität Erlangen-Nürnberg (1) · Ivano-Frankivsk National Medical University (1) · Kafrelsheikh University (1) · Leigh Sowerby (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Technische Universität Dresden (1) · The Parkinson's Institute (1) · University Medical Center Groningen (1) · University Of Perugia (1) · University of California, San Francisco (1)
United States (3) · Canada (2) · Egypt (2) · China (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Saudi Arabia (1) · Ukraine (1)
Davangere Devanand, M.D. (2) · A KL Reyners, MD, PhD (1) · Andrew Goldberg, MD (1) · Christian Trichard (1) · Emad R Issak, MD (1) · Grace S Liang, MD (1) · Gregory Pelton, M.D. (1) · Heinz Reichmann, MD, PhD (1) · Leigh Sowerby, MD, FRCSC (1) · Mahmoud Elkazzaz, M.Sc of Biochemistry (1) · Tamer Haydara, Ass/Prof of Internal medicine (1) · Vasyl Popovych, Professor (1)
PMID 32333591, PMID 36062970, PMID 37990964
2008 (1), R01AG041795 (1)